United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$397.49 USD
+14.72 (3.85%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$397.49 USD
+14.72 (3.85%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Zacks News
4 Finest Value Stocks Based on Discounted PEG
by Urmimala Biswas
A lower PEG ratio, preferably less than 1, indicates both undervaluation and solid future growth potential of a stock.
Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.
United Therapeutics (UTHR) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -51.42% and -11.10%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will United Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in United Therapeutics.
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y
by Zacks Equity Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.
Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
5 Stocks in Focus on Remarkable Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
New Strong Buy Stocks for February 14th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod
by Zacks Equity Research
Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Why United Therapeutics (UTHR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.
Arena (ARNA) Expands Strategic Deal With Beacon Discovery
by Zacks Equity Research
Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.
Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.
United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) beats estimates on both fronts in the third quarter. Stock rises in response
Will United Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor United Therapeutics.
Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial
by Zacks Equity Research
Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial
United Therapeutics (UTHR) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.63% and 19.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q3 results.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Solid Relative Price Strength Stocks to Make You Rich
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
United Therapeutics' Trevyent NDA for PAH Accepted by FDA
by Zacks Equity Research
United Therapeutics (UTHR) announces acceptance of Trevyent NDA by the FDA for pulmonary arterial hypertension.